New HIV, Hepatitis and Syphilis Diagnostic landscape and market report highlights significant gains in diagnostic access and demand leading into 2025, and diversified country action to adjust to new reality.

HIV, viral hepatitis, and syphilis (HHS) diseases remain critical public health challenges, causing 2.3 million deaths and 1.2 million cancer cases annually. However, increased testing volumes and innovations in diagnostic tools signal significant progress in addressing these issues, as highlighted by a new report on the Integrated_HHS_Diagnostic_landscape.

The report, developed by the World Health Organization (WHO) and Eureka Idea Co. provides an overview of the ongoing policy, programmatic and technological developments that are shaping the HIV, Syphilis and Hepatitis diagnostic access and markets at a global level. The report covers several different market segments, reflecting the growing complexity of diagnostic needs in low- and middle-income countries (LMICs). In doing so it highlights the achievements that have improved access, equity, and sustainability in these markets, the missed opportunities that need to be prioritised and the implications of the changing funding landscape.

Additionally this report is instrumental for understanding the scale of the potential impact of the USAID shut-down on HIV, Heaptitis and Syphilis diagnostic procurement in LMICs. The report provides an assessment of national level exposure to the USAID procurement system for diagnostics, plus the past funding and procurement levels by USAID of each diagnostic test type assessed, and the actions being taken nationally to address funding shortfalls and strengthen national procurement and supply systems.